Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn�s disease. A real life study

Abstract

this real-life study shows the association between ustekinumab trough concentration and clinical and biochemical remission and we suggest an optimal cut-off point higher than 2.2 µg/ml. Further studies are needed to confirm the findings and to identify the optimal cut-off in different disease outcomes and disease phenotypes.